The Global Pulmonary Hypertension and Rare Disease (PH & RD) organization leads the global commercial efforts for our first-in-class activin signaling inhibitor approved for the treatment of Pulmonary Arterial Hypertension (PAH) in many markets across the globe, which is in the middle of our global launch and has the potential to transform the PAH landscape. Earlier this year, the company presented successful results from the Phase 2 CADENCE study in combined pre- and post-capillary pulmonary hypertension associated with heart failure with preserved ejection fraction (CpcPH-HFpEF) and shared its intent to move this indication into phase 3. The Director of Life Cycle Management (LCM) & Future Strategy for Pulmonary Hypertension (PH) & Rare Disease will play an integral role on the Global Marketing team, with responsibility for advancing early commercialization development for potential future indications for this compound. The role requires strategic leadership, strong collaboration with U.S. and local market teams, and close partnership with Clinical, Medical Affairs, Market Access, Digital Human Health, and other key stakeholders.
Stand Out From the Crowd
Upload your resume and get instant feedback on how well it matches this job.
Job Type
Full-time
Career Level
Director